BLC
MCID: BLD134
MIFTS: 70

Bladder Cancer (BLC)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Bladder Cancer

MalaCards integrated aliases for Bladder Cancer:

Name: Bladder Cancer 57 12 53 25 75 37 55 43 15 38
Bladder Carcinoma 38 12 29 55 6 15
Bladder Cancer, Somatic 57 29 13 6
Urinary Bladder Cancer 12 25 75 15
Carcinoma of Bladder 12 73
Bladder Neoplasm 76 73
Malignant Neoplasm of Urinary Bladder 73
Urothelial Carcinoma of the Bladder 75
Malignant Tumor of Urinary Bladder 25
Carcinoma of Urinary Bladder 12
Urinary Bladder Neoplasms 44
Cancer of the Bladder 25
Tumor of the Bladder 12
Carcinoma Bladder 12
Cancer, Bladder 40
Bladder Tumors 55
Blc 75

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant (11p)


HPO:

32
bladder cancer:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 109800
Disease Ontology 12 DOID:11054 DOID:4007
ICD10 33 C67 C67.9
ICD9CM 35 188 188.9
MeSH 44 D001749
SNOMED-CT 68 93689003
MedGen 42 C0005684
KEGG 37 H00022
SNOMED-CT via HPO 69 263681008 255109008

Summaries for Bladder Cancer

MedlinePlus : 43 The bladder is a hollow organ in your lower abdomen that stores urine. Bladder cancer occurs in the lining of the bladder. It is the sixth most common type of cancer in the United States. Symptoms include Blood in your urine A frequent urge to urinate Pain when you urinate Low back pain Risk factors for developing bladder cancer include smoking and exposure to certain chemicals in the workplace. People with a family history of bladder cancer or who are older, white, or male have a higher risk. Treatments for bladder cancer include surgery, radiation therapy, chemotherapy, and biologic therapy. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

MalaCards based summary : Bladder Cancer, also known as bladder carcinoma, is related to transitional cell carcinoma and bladder adenocarcinoma. An important gene associated with Bladder Cancer is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Bladder cancer and MicroRNAs in cancer. The drugs Valstar and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include prostate, lymph node and testes, and related phenotype is transitional cell carcinoma of the bladder.

Disease Ontology : 12 An urinary system cancer that results in malignant growth located in the urinary bladder.

Genetics Home Reference : 25 Bladder cancer is a disease in which certain cells in the bladder become abnormal and multiply without control or order. The bladder is a hollow, muscular organ in the lower abdomen that stores urine until it is ready to be excreted from the body. The most common type of bladder cancer begins in cells lining the inside of the bladder and is called transitional cell carcinoma (TCC).

NIH Rare Diseases : 53 Bladder cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the bladder. Signs and symptoms of the condition may include abdominal pain, blood in the urine, fatigue, painful urination, frequent urination, incontinence, and/or weightloss. Most cases of bladder cancer occur sporadically in people with no family history of the condition. Risk factors for the condition include smoking, exposure to certain chemicals, and having chronic bladder infections. Treatment varies based on the severity of the condition and may include surgery, radiation therapy, chemotherapy, and/or biological therapy.

UniProtKB/Swiss-Prot : 75 Bladder cancer: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.

Wikipedia : 76 Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder. It is... more...

Description from OMIM: 109800

Related Diseases for Bladder Cancer

Diseases in the Bladder Cancer family:

Bladder Benign Neoplasm Bladder Carcinoma in Situ

Diseases related to Bladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 387)
# Related Disease Score Top Affiliating Genes
1 transitional cell carcinoma 32.6 HRAS FGFR3 BRINP1
2 bladder adenocarcinoma 31.8 UCA1 HRAS
3 prostate cancer 30.9 UCA1 TUG1 RB1 MIR221 MIR21 MIR143
4 bladder urothelial carcinoma 30.9 TUG1 RB1 MALAT1 KRAS HRAS FGFR3
5 renal cell carcinoma, nonpapillary 30.8 UCA1 TUG1 TSC1 MALAT1 H19
6 lung cancer 30.8 ZEB2-AS1 UCA1 TUG1 RB1 MIR221 MIR21
7 squamous cell carcinoma 30.6 UCA1 TUG1 RB1 MALAT1 HRAS H19
8 adenocarcinoma 30.4 RB1 MALAT1 KRAS HRAS H19 FGFR3
9 melanoma 30.3 UCA1 MIR221 MIR127 MALAT1 H19
10 kidney cancer 30.3 MIR21 MALAT1 H19
11 gallbladder cancer 30.3 UCA1 TUG1 MALAT1 KRAS H19
12 nevus, epidermal 30.1 KRAS HRAS FGFR3
13 myeloma, multiple 30.1 UCA1 TUG1 MALAT1 KRAS HRAS H19
14 lung cancer susceptibility 3 30.1 TUG1 MALAT1 KRAS HRAS H19 FGFR3
15 leukemia, chronic lymphocytic 2 30.1 MIR143 KRAS HRAS
16 cervical cancer 30.1 UCA1 TUG1 RB1 MIR21 MIR143 MALAT1
17 small cell cancer of the lung 30.1 TUG1 RB1 MIR21 MALAT1
18 gastric cancer 30.0 UCA1 TUG1 MIR221 MIR21 MIR143 MALAT1
19 glioblastoma 30.0 TUG1 RB1 MIR221 MIR21 MIR10B MALAT1
20 polymyositis 30.0 MIR21 MIR127
21 colorectal cancer 30.0 UCA1 TUG1 MIR221 MIR21 MIR143 MIR127
22 breast cancer 29.9 UCA1 TUG1 RB1 MIR221 MIR21 MIR143
23 ovarian cancer 29.9 UCA1 TUG1 MIR221 MIR21 MIR143 MIR127
24 superficial urinary bladder cancer 12.2
25 jewett-marshall bladder cancer 12.1
26 bladder cancer, childhood 12.1
27 gall bladder carcinoma in situ 12.0
28 small cell carcinoma of the bladder 11.9
29 chondrodysplasia, blomstrand type 11.8
30 schistosomiasis 11.3
31 urinary bladder small cell neuroendocrine carcinoma 11.3
32 urinary schistosomiasis 11.2
33 urachal cancer 11.1
34 pseudo-torch syndrome 1 11.1
35 congenital intrauterine infection-like syndrome 11.1
36 bladder verrucous squamous cell carcinoma 11.0
37 bladder squamous cell carcinoma 11.0
38 bladder urachal squamous cell carcinoma 11.0
39 bladder urachal carcinoma 11.0
40 bladder urachal urothelial carcinoma 11.0
41 danubian endemic familial nephropathy 10.9
42 bladder disease 10.9
43 neuroschistosomiasis 10.9
44 adenosquamous lung carcinoma 10.5 KRAS HRAS FGFR3
45 sigmoid neoplasm 10.4 KRAS HRAS
46 squamous cell carcinoma, head and neck 10.4 RB1 MIR221 MIR21 HRAS H19 FGFR3
47 lung squamous cell carcinoma 10.4 TUG1 KRAS HRAS FGFR3
48 endometrial cancer 10.4 UCA1 TUG1 RB1 KRAS HRAS H19
49 non-papillary transitional cell carcinoma of the bladder 10.4
50 apocrine adenoma 10.4 KRAS HRAS

Comorbidity relations with Bladder Cancer via Phenotypic Disease Network (PDN): (show all 20)


Acute Cystitis Acute Kidney Failure
Bladder Neck Obstruction Chronic Kidney Failure
Chronic Myocardial Ischemia Cystitis
Cystitis Cystica Deficiency Anemia
Hydronephrosis Ischemic Heart Disease
Neutropenia Paralytic Ileus
Prostate Cancer Prostatic Hypertrophy
Radiation Cystitis Renal Pelvis Carcinoma
Ureter, Cancer of Urethral Benign Neoplasm
Urethral Stricture Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Bladder Cancer:



Diseases related to Bladder Cancer

Symptoms & Phenotypes for Bladder Cancer

Symptoms via clinical synopsis from OMIM:

57
G U:
transitional cell bladder carcinoma


Clinical features from OMIM:

109800

Human phenotypes related to Bladder Cancer:

32
# Description HPO Frequency HPO Source Accession
1 transitional cell carcinoma of the bladder 32 HP:0006740

Drugs & Therapeutics for Bladder Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Valstar 18 VALRUBICIN Anthra Pharmaceuticals October 1998

Drugs for Bladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 521)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
2
Midazolam Approved, Illicit Phase 4,Phase 2 59467-70-8 4192
3
Epirubicin Approved Phase 4,Phase 3,Phase 2,Not Applicable 56420-45-2 41867
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15663-27-1 2767 441203 84093
5
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3 1197-18-8 5526
6
Pioglitazone Approved, Investigational Phase 4,Phase 2 111025-46-8 4829
7
Metformin Approved Phase 4,Phase 2,Early Phase 1 657-24-9 14219 4091
8
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
9
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
10
Rocuronium Approved Phase 4,Not Applicable 119302-91-9, 143558-00-3 441290
11
Benzocaine Approved, Investigational Phase 4,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
12 tannic acid Approved Phase 4,Phase 2,Not Applicable
13
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 137-58-6 3676
14
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
15
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
16
Ofloxacin Approved Phase 4 82419-36-1 4583
17
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
18
Piroxicam Approved, Investigational Phase 4 36322-90-4 54676228 5280452
19
Lornoxicam Approved, Investigational Phase 4 70374-39-9 5282204
20
Praziquantel Approved, Investigational, Vet_approved Phase 4 55268-74-1 4891
21
Parecoxib Approved Phase 4 198470-84-7
22
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
23
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
24
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
25
Mebeverine Approved, Investigational Phase 4 3625-06-7 62887
26
Alverine Approved, Investigational Phase 4 150-59-4 3678
27
Alogliptin Approved Phase 4 850649-61-5 11450633
28
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
29
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
30
BCG vaccine Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
31
2,4-thiazolidinedione Investigational Phase 4,Phase 2 2295-31-0
32
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
33
Fibrinolysin Investigational Phase 4 9004-09-5
34 Narcotics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
35 Anesthetics Phase 4,Phase 2,Phase 3,Not Applicable
36 Hypnotics and Sedatives Phase 4,Not Applicable
37 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
40 Analgesics, Opioid Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
41 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
42 Mitomycins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Coagulants Phase 4,Phase 2,Phase 3
47 Hemostatics Phase 4,Phase 2,Phase 3,Not Applicable
48 Neuromuscular Blocking Agents Phase 4,Not Applicable
49 Neuromuscular Agents Phase 4,Not Applicable
50 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1087)
# Name Status NCT ID Phase Drugs
1 The Assessment of POCD After TURBT Under Spinal Anesthesia Unknown status NCT03029676 Phase 4 benzodiazepines;opioid
2 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
3 Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression Recruiting NCT02443844 Phase 4 Tamsulosin
4 Sequential Combination Therapy in Bladder Cancer Not yet recruiting NCT03790384 Phase 4 Mitomycin
5 Laser En Bloc Resection Of Bladder Tumor (HoLERBT) VS. Conventional Transurethral Resection Of Bladder Tumors (cTURBT) Recruiting NCT02555163 Phase 4
6 Recurrence of Bladder Cancer After Transurethral Resection With Hexvix Withdrawn NCT00785694 Phase 4 hexaminolevulinate
7 Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer Completed NCT02214602 Phase 4 Epirubicin
8 Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer. Completed NCT02001857 Phase 4 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.
9 Chemoradiotherapy for Recurrent T1G3 Bladder Cancer Not yet recruiting NCT03274284 Phase 4
10 Neuromuscular Blockade During Transurethral Resection of Bladder Cancer Completed NCT03039543 Phase 4 Rocuronium;Sugammadex
11 "En Bloc" Resection of NMIBC: a Prospective, Single Centre,Randomized Study Not yet recruiting NCT03221062 Phase 4
12 In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both? Completed NCT03174912 Phase 4
13 Ultrasound-Guided ONB for Transurethral Procedures - Interadductor Approach Recruiting NCT02696733 Phase 4 lidocaine 2%;0.9% Natrium Chloratum with a 2nd generation cephalosporin
14 Investigation of Sugammadex in Outpatient Urological Procedures Recruiting NCT03138967 Phase 4 Rocuronium;Sugammadex;Neostigmine;Glycopyrrolate
15 Peri-operative Aspirin Continuation Versus Discontinuation Enrolling by invitation NCT02350543 Phase 4 Aspirin
16 Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects? Active, not recruiting NCT03038321 Phase 4 sofenacin;Tavanic;Xefo
17 Safety and Efficacy of Intravenous Tranexamic Acid in Endoscopic Transurethral Resections in Urology Completed NCT02653261 Phase 4 Tranexamic Acid;Placebo
18 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis Withdrawn NCT02734186 Phase 4 Praziquantel
19 Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy Active, not recruiting NCT03147586 Phase 4 Bio-tech and omega-3 plus;placebo
20 Carotene and Retinol Efficacy Trial Completed NCT00712647 Phase 4 Beta Carotene and Retinol
21 Parecoxib for Treatment of Catheter Related Bladder Discomfort Completed NCT02729935 Phase 4 Parecoxib;Placebo
22 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
23 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
24 Effects of a Neuroscience-based Technique on Post-traumatic Stress Disorder Symptoms, Inflammation, and Survival in Cancer Patients Announced of a Palliative Disease Progression and Their Partners Recruiting NCT03652298 Phase 4
25 Mebeverine For Daytime And Nocturnal Incontinence and After Orthotopic W-Ileal Neobladders Recruiting NCT03147599 Phase 4 Coloverin;Placebo
26 The Practical Evidence of Antidiabetic Combination Therapy in Korea Recruiting NCT02231021 Phase 4 alogliptin;Pioglitazone;alogliptin + pioglitazone
27 A Study of Comparing Effects of Thulium Laser en Bloc Resection and Electrical Transurethral Resection of the Non-muscle Invasive Bladder Cancer Unknown status NCT02951078 Phase 3
28 Clinical Trial Using Bipolar Technology for Transurethral Resection of Bladder Tumor Unknown status NCT01581723 Phase 3
29 Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer Unknown status NCT00553124 Phase 3 selenium;vitamin E
30 Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer Unknown status NCT00553345 Phase 3 selenium;vitamin E
31 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
32 Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
33 Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection Unknown status NCT00816075 Phase 2, Phase 3 distilled water
34 Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Unknown status NCT00003725 Phase 3 valrubicin
35 The Impact of Early Feeding After Radical Cystectomy for Bladder Cancer Unknown status NCT01489800 Phase 3
36 A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
37 Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Unknown status NCT00146276 Phase 3 gemcitabine
38 Neobladder Posterior Wall Suspended With Round Ligament of Uterus After Radical Cystectomy in Female With Bladder Cancer —a Prospective Control Study Unknown status NCT01273987 Phase 2, Phase 3
39 Tranexamic Acid During Cystectomy Trial (TACT) Unknown status NCT01869413 Phase 2, Phase 3 Tranexamic Acid;Placebo
40 Efficacy of Diclofenac BCG Irrigations Unknown status NCT01542567 Phase 3 Abitren;Placebo
41 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
42 Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9) Recruiting NCT01675219 Phase 3 optimized MMC;single immediate chemotherapy instillation
43 Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer Not yet recruiting NCT03664869 Phase 3 BCG instillation therapy;Sequential BCG and EMDA mitomycin C
44 Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer Not yet recruiting NCT03298958 Phase 3 Rapamycin;Placebo Oral Tablet
45 Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer Completed NCT00729287 Phase 3
46 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
47 Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612) Completed NCT00598806 Phase 3 Apaziquone;Placebo
48 Assessment of BladderLight SurvEILlance Not yet recruiting NCT03427034 Phase 2, Phase 3
49 Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611) Completed NCT00461591 Phase 3 Apaziquone;Placebo
50 High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer Completed NCT00003623 Phase 3

Search NIH Clinical Center for Bladder Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bladder Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bladder Cancer:
Neo-Urinary Conduit�, smooth muscle cell 3D culture for bladder diseases
Embryonic/Adult Cultured Cells Related to Bladder Cancer:
Neo-Urinary Conduit� PMIDs: 22136657

Cochrane evidence based reviews: urinary bladder neoplasms

Genetic Tests for Bladder Cancer

Genetic tests related to Bladder Cancer:

# Genetic test Affiliating Genes
1 Bladder Cancer, Somatic 29 FGFR3 HRAS KRAS RB1
2 Bladder Carcinoma 29

Anatomical Context for Bladder Cancer

MalaCards organs/tissues related to Bladder Cancer:

41
Prostate, Lymph Node, Testes, Lung, T Cells, Endothelial, Breast

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Cancer:

19
The Urinary Bladder

Publications for Bladder Cancer

Articles related to Bladder Cancer:

(show top 50) (show all 5564)
# Title Authors Year
1
Knockdown of long non-coding RNA metastasis associated lung adenocarcinoma transcript 1 inhibits the proliferation and migration of bladder cancer cells by modulating the microRNA-34a/cyclin D1 axis. ( 30387807 )
2019
2
Oxidative nucleophilic substitution selectively produces cambinol derivatives with antiproliferative activity on bladder cancer cell lines. ( 30442421 )
2019
3
Tetramodal therapy using balloon-occluded arterial infusion of anticancer agents, the Azuma regimen, for lymph node-involved bladder cancer. ( 30387836 )
2019
4
Upregulation of lncRNA snoRNA host gene 6 regulates NUAK family SnF1-like kinase-1 expression by competitively binding microRNA-125b and interacting with Snail1/2 in bladder cancer. ( 30168179 )
2019
5
Urinary cell-free microRNA biomarker could discriminate bladder cancer from benign hematuria. ( 30183088 )
2019
6
miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer. ( 30194772 )
2019
7
The long noncoding RNA HIF1A-AS2 facilitates cisplatin resistance in bladder cancer. ( 30216500 )
2019
8
Down-regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP-1c axis. ( 30221356 )
2019
9
LncRNA PVT1 regulates VEGFC through inhibiting miR-128 in bladder cancer cells. ( 30076714 )
2019
10
Activation of type 4 metabotropic glutamate receptor promotes cell apoptosis and inhibits proliferation in bladder cancer. ( 30145816 )
2019
11
Long non-coding RNA cartilage injury-related promotes malignancy in bladder cancer. ( 29435036 )
2018
12
Apparent diffusion coefficient values obtained by unenhanced MRI predicts disease-specific survival in bladder cancer. ( 29970242 )
2018
13
Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer. ( 29438376 )
2018
14
NLS-cholic acid conjugation to IL-5RI+-specific antibody improves cellular accumulation and in vivo tumor-targeting properties in a bladder cancer model. ( 29433309 )
2018
15
The long non-coding RNA FOXD2-AS1 promotes bladder cancer progression and recurrence through a positive feedback loop with Akt and E2F1. ( 29445134 )
2018
16
Genome-wide identification of urinary cell-free microRNAs for non-invasive detection of bladder cancer. ( 29363887 )
2018
17
Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation. ( 29387931 )
2018
18
Pre-diagnostic circulating insulin-like growth factor-I and bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition. ( 29971779 )
2018
19
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. ( 29976469 )
2018
20
Single ablative intravesical electromotive mitomycin C administration for small non-muscle-invasive bladder cancer: a prospective study. ( 29451102 )
2018
21
Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells. ( 29966976 )
2018
22
Leupaxin Promotes Bladder Cancer Proliferation, Metastasis, and Angiogenesis Through the PI3K/AKT Pathway. ( 29975926 )
2018
23
Long-term outcomes of high grade T1 bladder cancer treated with intravesical Bacille Calmette-Guerin therapy: a single-institutional experience. ( 29968999 )
2018
24
Evaluation of therapeutic effects of<sup>125</sup>I particles brachytherapy for recurrent bladder cancer. ( 29435083 )
2018
25
Diagnostic performance of diffusion-weighted MR imaging at 3.0A T in predicting muscle invasion in urinary bladder cancer: utility of evaluating the morphology of the reactive tumor stalk. ( 29392362 )
2018
26
Enhanced recovery after surgery for radical cystectomy with ileal urinary diversion: a multi-institutional, randomized, controlled trial from the Chinese bladder cancer consortium. ( 29080948 )
2018
27
Transactivation of PTGS2 by PAX5 signaling potentiates cisplatin resistance in muscle-invasive bladder cancer cells. ( 29964012 )
2018
28
Genipin inhibits the growth of human bladder cancer cells via inactivation of PI3K/Akt signaling. ( 29434982 )
2018
29
The role of adjuvant chemotherapy in locally advanced bladder cancer. ( 29226744 )
2018
30
Molecular Landscape of Non-Muscle Invasive Bladder Cancer. ( 29430514 )
2018
31
Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis. ( 28958829 )
2018
32
Potential effect modifiers of the arsenic-bladder cancer risk relationship. ( 29981168 )
2018
33
CXCL5 promotes mitomycin C resistance in non-muscle invasive bladder cancer by activating EMT and NF-I_B pathway. ( 29545183 )
2018
34
Promoter methylation of DNA damage repair (DDR) genes in human tumor entities:<i>RBBP8</i>/<i>CtIP</i>is almost exclusively methylated in bladder cancer. ( 29445424 )
2018
35
Complications within 90A days after radical cystectomy for bladder cancer: results of a multicenter prospective study in Japan. ( 29442282 )
2018
36
Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy. ( 29491095 )
2018
37
Value of repeat radical transurethral resection for selected patients with muscle-invasive bladder cancer. ( 29974604 )
2018
38
Increased expression of GGN promotes tumorigenesis in bladder cancer and is correlated with poor prognosis. ( 29412153 )
2018
39
Clinical evaluation of two consecutive UroVysion fluorescence in situ hybridization tests to detect intravesical recurrence of bladder cancer: a prospective blinded comparative study in Japan. ( 29971622 )
2018
40
HBO1 promotes cell proliferation in bladder cancer via activation of Wnt/I^-catenin signaling. ( 28796367 )
2018
41
Ecto-5'-nucleotidase/CD73 contributes to the radiosensitivity of T24 human bladder cancer cell line. ( 29305710 )
2018
42
Prognostic significance of HALP (hemoglobin, albumin, lymphocyte and platelet) in patients with bladder cancer after radical cystectomy. ( 29335609 )
2018
43
Cancer Immune Therapy: Prognostic Significance and Implications for Therapy of PD-1 in BCG-Relapsing Bladder Cancer. ( 29971674 )
2018
44
KIRs gene content diversity in Iranians with urothelial bladder cancer. ( 29968117 )
2018
45
Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer. ( 29971464 )
2018
46
Bladder cancer: BBN mouse model mimics human MIBC. ( 29434365 )
2018
47
Patient-reported Outcomes of Blue Light Flexible Cystoscopy with Hexaminolevulinate (HAL) in the Surveillance of Bladder Cancer: Results from a Prospective Multi-center Study. ( 29979488 )
2018
48
Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. ( 29133939 )
2018
49
Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery. ( 29451296 )
2018
50
Emerging role of Hippo signalling pathway in bladder cancer. ( 28782275 )
2018

Variations for Bladder Cancer

UniProtKB/Swiss-Prot genetic disease variations for Bladder Cancer:

75
# Symbol AA change Variation ID SNP ID
1 FGFR3 p.Arg248Cys VAR_004148 rs121913482
2 FGFR3 p.Ser249Cys VAR_004149 rs121913483
3 FGFR3 p.Gly370Cys VAR_004151 rs121913479
4 FGFR3 p.Lys650Glu VAR_004160 rs78311289
5 FGFR3 p.Lys650Gln VAR_018390 rs78311289

ClinVar genetic disease variations for Bladder Cancer:

6 (show top 50) (show all 131)
# Gene Variation Type Significance SNP ID Assembly Location
1 FGFR3 NM_000142.4(FGFR3): c.1111A> T (p.Ser371Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913484 GRCh37 Chromosome 4, 1806092: 1806092
2 FGFR3 NM_000142.4(FGFR3): c.1111A> T (p.Ser371Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913484 GRCh38 Chromosome 4, 1804365: 1804365
3 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 GRCh37 Chromosome 4, 1803568: 1803568
4 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 GRCh38 Chromosome 4, 1801841: 1801841
5 FGFR3 NM_000142.4(FGFR3): c.1118A> G (p.Tyr373Cys) single nucleotide variant Pathogenic rs121913485 GRCh37 Chromosome 4, 1806099: 1806099
6 FGFR3 NM_000142.4(FGFR3): c.1118A> G (p.Tyr373Cys) single nucleotide variant Pathogenic rs121913485 GRCh38 Chromosome 4, 1804372: 1804372
7 FGFR3 NM_000142.4(FGFR3): c.1948A> C (p.Lys650Gln) single nucleotide variant Pathogenic rs78311289 GRCh37 Chromosome 4, 1807889: 1807889
8 FGFR3 NM_000142.4(FGFR3): c.1948A> C (p.Lys650Gln) single nucleotide variant Pathogenic rs78311289 GRCh38 Chromosome 4, 1806162: 1806162
9 FGFR3 NM_000142.4(FGFR3): c.1108G> T (p.Gly370Cys) single nucleotide variant Pathogenic rs121913479 GRCh37 Chromosome 4, 1806089: 1806089
10 FGFR3 NM_000142.4(FGFR3): c.1108G> T (p.Gly370Cys) single nucleotide variant Pathogenic rs121913479 GRCh38 Chromosome 4, 1804362: 1804362
11 TSC1 NM_000368.4(TSC1): c.132dupC (p.Val46Glyfs) duplication not provided rs118203337 GRCh37 Chromosome 9, 135802666: 135802666
12 TSC1 NM_000368.4(TSC1): c.132dupC (p.Val46Glyfs) duplication not provided rs118203337 GRCh38 Chromosome 9, 132927279: 132927279
13 TSC1 NM_000368.4(TSC1): c.1354G> C (p.Gly452Arg) single nucleotide variant not provided rs118203519 GRCh37 Chromosome 9, 135782202: 135782202
14 TSC1 NM_000368.4(TSC1): c.1354G> C (p.Gly452Arg) single nucleotide variant not provided rs118203519 GRCh38 Chromosome 9, 132906815: 132906815
15 FGFR3 NM_001163213.1(FGFR3): c.2095G> T (p.Gly699Cys) single nucleotide variant Likely pathogenic rs121913480 GRCh37 Chromosome 4, 1808331: 1808331
16 FGFR3 NM_001163213.1(FGFR3): c.2095G> T (p.Gly699Cys) single nucleotide variant Likely pathogenic rs121913480 GRCh38 Chromosome 4, 1806604: 1806604
17 MRE11 NM_005590.3(MRE11): c.1098+1408A> G single nucleotide variant other rs200367125 GRCh38 Chromosome 11, 94466405: 94466405
18 TSC1 NM_000368.4(TSC1): c.664-1G> A single nucleotide variant Pathogenic rs118203423 GRCh38 Chromosome 9, 132921437: 132921437
19 TSC1 NM_000368.4(TSC1): c.664-1G> A single nucleotide variant Pathogenic rs118203423 GRCh37 Chromosome 9, 135796824: 135796824
20 TSC1 NM_000368.4(TSC1): c.663+1G> A single nucleotide variant Pathogenic/Likely pathogenic rs118203419 GRCh38 Chromosome 9, 132921818: 132921818
21 TSC1 NM_000368.4(TSC1): c.663+1G> A single nucleotide variant Pathogenic/Likely pathogenic rs118203419 GRCh37 Chromosome 9, 135797205: 135797205
22 TSC1 NM_000368.4(TSC1): c.569delG (p.Arg190Profs) deletion not provided rs118203401 GRCh38 Chromosome 9, 132921913: 132921913
23 TSC1 NM_000368.4(TSC1): c.569delG (p.Arg190Profs) deletion not provided rs118203401 GRCh37 Chromosome 9, 135797300: 135797300
24 TSC1 NM_000368.4(TSC1): c.524dupT (p.Tyr176Leufs) duplication not provided rs118203393 GRCh38 Chromosome 9, 132921958: 132921958
25 TSC1 NM_000368.4(TSC1): c.524dupT (p.Tyr176Leufs) duplication not provided rs118203393 GRCh37 Chromosome 9, 135797345: 135797345
26 TSC1 NM_000368.4(TSC1): c.489A> T (p.Ser163=) single nucleotide variant not provided rs118203386 GRCh38 Chromosome 9, 132923367: 132923367
27 TSC1 NM_000368.4(TSC1): c.489A> T (p.Ser163=) single nucleotide variant not provided rs118203386 GRCh37 Chromosome 9, 135798754: 135798754
28 TSC1 NM_000368.4(TSC1): c.473T> G (p.Phe158Cys) single nucleotide variant not provided rs118203385 GRCh38 Chromosome 9, 132923383: 132923383
29 TSC1 NM_000368.4(TSC1): c.473T> G (p.Phe158Cys) single nucleotide variant not provided rs118203385 GRCh37 Chromosome 9, 135798770: 135798770
30 TSC1 NM_000368.4(TSC1): c.3324C> T (p.Gly1108=) single nucleotide variant Benign rs35593170 GRCh38 Chromosome 9, 132896406: 132896406
31 TSC1 NM_000368.4(TSC1): c.3324C> T (p.Gly1108=) single nucleotide variant Benign rs35593170 GRCh37 Chromosome 9, 135771793: 135771793
32 TSC1 NM_000368.4(TSC1): c.3303G> A (p.Glu1101=) single nucleotide variant Benign/Likely benign rs118203751 GRCh38 Chromosome 9, 132896427: 132896427
33 TSC1 NM_000368.4(TSC1): c.3303G> A (p.Glu1101=) single nucleotide variant Benign/Likely benign rs118203751 GRCh37 Chromosome 9, 135771814: 135771814
34 TSC1 NM_000368.4(TSC1): c.3030G> T (p.Glu1010Asp) single nucleotide variant not provided rs118203741 GRCh38 Chromosome 9, 132896700: 132896700
35 TSC1 NM_000368.4(TSC1): c.3030G> T (p.Glu1010Asp) single nucleotide variant not provided rs118203741 GRCh37 Chromosome 9, 135772087: 135772087
36 TSC1 NM_000368.4(TSC1): c.2829C> T (p.Ala943=) single nucleotide variant Benign rs4962081 GRCh38 Chromosome 9, 132897330: 132897330
37 TSC1 NM_000368.4(TSC1): c.2829C> T (p.Ala943=) single nucleotide variant Benign rs4962081 GRCh37 Chromosome 9, 135772717: 135772717
38 TSC1 NM_000368.4(TSC1): c.2646C> T (p.Ala882=) single nucleotide variant Conflicting interpretations of pathogenicity rs118203720 GRCh38 Chromosome 9, 132897590: 132897590
39 TSC1 NM_000368.4(TSC1): c.2646C> T (p.Ala882=) single nucleotide variant Conflicting interpretations of pathogenicity rs118203720 GRCh37 Chromosome 9, 135772977: 135772977
40 TSC1 NM_000368.4(TSC1): c.2625+1G> A single nucleotide variant not provided rs118203715 GRCh38 Chromosome 9, 132900714: 132900714
41 TSC1 NM_000368.4(TSC1): c.2625+1G> A single nucleotide variant not provided rs118203715 GRCh37 Chromosome 9, 135776101: 135776101
42 TSC1 NM_000368.4(TSC1): c.245A> C (p.Lys82Thr) single nucleotide variant not provided rs118203356 GRCh38 Chromosome 9, 132925705: 132925705
43 TSC1 NM_000368.4(TSC1): c.245A> C (p.Lys82Thr) single nucleotide variant not provided rs118203356 GRCh37 Chromosome 9, 135801092: 135801092
44 TSC1 NM_000368.4(TSC1): c.2074C> T (p.Arg692Ter) single nucleotide variant Pathogenic rs118203631 GRCh38 Chromosome 9, 132903785: 132903785
45 TSC1 NM_000368.4(TSC1): c.2074C> T (p.Arg692Ter) single nucleotide variant Pathogenic rs118203631 GRCh37 Chromosome 9, 135779172: 135779172
46 TSC1 NM_000368.4(TSC1): c.203A> G (p.His68Arg) single nucleotide variant not provided rs118203347 GRCh38 Chromosome 9, 132927208: 132927208
47 TSC1 NM_000368.4(TSC1): c.203A> G (p.His68Arg) single nucleotide variant not provided rs118203347 GRCh37 Chromosome 9, 135802595: 135802595
48 TSC1 NM_000368.4(TSC1): c.1997+71_1997+72del deletion not provided rs118203612 GRCh38 Chromosome 9, 132905509: 132905510
49 TSC1 NM_000368.4(TSC1): c.1997+71_1997+72del deletion not provided rs118203612 GRCh37 Chromosome 9, 135780896: 135780897
50 TSC1 NM_000368.4(TSC1): c.1958_1959delTA (p.Ile653Thrfs) deletion not provided rs118203602 GRCh38 Chromosome 9, 132905619: 132905620

Copy number variations for Bladder Cancer from CNVD:

7 (show top 50) (show all 98)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14770 1 110031964 110037890 Decreasing copy number GSTM1 Bladder cancer
2 16660 1 128900000 185800000 Gain Bladder cancer
3 18051 1 143699872 161705044 Gain Bladder cancer
4 36534 1 77068898 77170790 Loss Bladder cancer
5 51778 11 130615965 132678521 Loss Bladder cancer
6 53648 11 31517796 32050223 Loss Bladder cancer
7 58531 11 68323054 69297218 Gain Bladder cancer
8 67850 12 45466239 58591220 Gain Bladder cancer
9 75136 13 16000000 114142980 Copy number Bladder cancer
10 79497 13 72534137 72746128 Gain Bladder cancer
11 80757 13 97270228 100084626 Gain Bladder cancer
12 81341 14 101619009 102408085 Loss Bladder cancer
13 83177 14 19364851 19446107 Loss Bladder cancer
14 87829 14 77750645 79747731 Loss Bladder cancer
15 88246 14 88632756 89467875 Gain Bladder cancer
16 89915 15 19427350 19427409 Loss Bladder cancer
17 96847 15 95052889 95403459 Loss Bladder cancer
18 97491 16 10647794 11795463 Gain Bladder cancer
19 98997 16 22221235 32532138 Gain Bladder cancer
20 101674 16 45413780 45607724 Gain Bladder cancer
21 101856 16 46548299 69323131 Loss Bladder cancer
22 103047 16 5996067 6407032 Loss Bladder cancer
23 104499 16 69543004 70813070 Gain Bladder cancer
24 107647 17 1649595 1725887 Loss Bladder cancer
25 109050 17 24000000 38100000 Gain Bladder cancer
26 109225 17 24641926 27576519 Gain Bladder cancer
27 112300 17 38521264 78444637 Gain Bladder cancer
28 118108 17 7571719 7590863 Loss TP53 Bladder cancer
29 121742 18 467310 796252 Gain Bladder cancer
30 122814 18 61643142 67432063 Loss Bladder cancer
31 126424 19 18749534 19294814 Gain Bladder cancer
32 127148 19 278073 12616127 Gain Bladder cancer
33 127869 19 37856935 63485510 Gain Bladder cancer
34 135679 2 11956730 12796508 Gain Bladder cancer
35 135959 2 123437325 126399586 Loss Bladder cancer
36 138231 2 159948195 160120757 Loss Bladder cancer
37 141850 2 217249378 242464793 Loss Bladder cancer
38 146581 2 51236117 51635693 Loss Bladder cancer
39 147190 2 60966923 61033726 Loss Bladder cancer
40 147284 2 62081310 62298660 Loss Bladder cancer
41 148163 2 74469 50579433 Loss Bladder cancer
42 150320 2 9872881 10505097 Gain Bladder cancer
43 150974 20 157771 456225 Gain Bladder cancer
44 151125 20 17870221 18440898 Gain Bladder cancer
45 151502 20 22093371 26036562 Gain Bladder cancer
46 152003 20 28081598 47163674 Gain Bladder cancer
47 154726 20 48033501 54958791 Gain Bladder cancer
48 156571 20 61727753 62175139 Gain Bladder cancer
49 158507 21 33581851 34132794 Gain Bladder cancer
50 160744 22 16259597 16597551 Loss Bladder cancer

Expression for Bladder Cancer

Search GEO for disease gene expression data for Bladder Cancer.

Pathways for Bladder Cancer

Pathways related to Bladder Cancer according to KEGG:

37
# Name Kegg Source Accession
1 Bladder cancer hsa05219
2 MicroRNAs in cancer hsa05206

GO Terms for Bladder Cancer

Cellular components related to Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.1 H19 MIR10B MIR127 MIR143 MIR21 MIR221

Biological processes related to Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.77 HRAS MIR21 MIR221 RB1 TSC1
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.73 FGFR3 HRAS MIR21 MIR221
3 Ras protein signal transduction GO:0007265 9.58 HRAS KRAS RB1
4 positive regulation of protein kinase B signaling GO:0051897 9.56 FGFR3 MIR143 MIR21 MIR221
5 striated muscle cell differentiation GO:0051146 9.46 KRAS RB1
6 gene silencing by miRNA GO:0035195 9.43 H19 MIR10B MIR127 MIR143 MIR21 MIR221
7 negative regulation of GTPase activity GO:0034260 9.33 HRAS MIR21 TSC1
8 response to isolation stress GO:0035900 9.32 HRAS KRAS
9 positive regulation of vascular associated smooth muscle cell migration GO:1904754 8.8 MIR143 MIR21 MIR221

Molecular functions related to Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.92 MIR10B MIR143 MIR21 MIR221

Sources for Bladder Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....